Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Common Variable Immunodeficiency | 5 | 2025 | 28 | 2.600 |
Why?
|
| Neoplasms | 12 | 2021 | 2780 | 2.020 |
Why?
|
| Fatigue | 3 | 2021 | 191 | 1.710 |
Why?
|
| Immunotherapy | 9 | 2023 | 675 | 1.650 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 556 | 1.520 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2022 | 205 | 1.320 |
Why?
|
| Immunologic Surveillance | 3 | 2021 | 15 | 0.940 |
Why?
|
| Hypersensitivity | 2 | 2022 | 185 | 0.840 |
Why?
|
| Angioedemas, Hereditary | 1 | 2022 | 8 | 0.820 |
Why?
|
| Angioedema | 1 | 2022 | 22 | 0.800 |
Why?
|
| Pneumonia | 2 | 2022 | 322 | 0.720 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 149 | 0.700 |
Why?
|
| Respiratory Tract Infections | 1 | 2022 | 270 | 0.640 |
Why?
|
| Bronchiectasis | 1 | 2019 | 23 | 0.630 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2018 | 144 | 0.610 |
Why?
|
| Sinusitis | 1 | 2019 | 116 | 0.570 |
Why?
|
| Trichosporon | 1 | 2017 | 5 | 0.570 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 702 | 0.570 |
Why?
|
| Trichosporonosis | 1 | 2017 | 8 | 0.560 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 116 | 0.560 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 128 | 0.560 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2017 | 65 | 0.540 |
Why?
|
| Brain Abscess | 1 | 2017 | 50 | 0.540 |
Why?
|
| Head | 1 | 2017 | 102 | 0.540 |
Why?
|
| Leukocytes | 1 | 2018 | 210 | 0.530 |
Why?
|
| Antibodies, Bacterial | 1 | 2018 | 388 | 0.510 |
Why?
|
| Immune System | 1 | 2017 | 90 | 0.510 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 90 | 0.510 |
Why?
|
| Immunoglobulins | 2 | 2022 | 173 | 0.500 |
Why?
|
| Streptococcus pneumoniae | 1 | 2018 | 375 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1032 | 0.490 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 775 | 0.490 |
Why?
|
| Antifungal Agents | 1 | 2017 | 288 | 0.470 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 117 | 0.470 |
Why?
|
| Young Adult | 16 | 2021 | 9023 | 0.460 |
Why?
|
| Quality of Life | 3 | 2018 | 1936 | 0.450 |
Why?
|
| Rare Diseases | 3 | 2021 | 191 | 0.450 |
Why?
|
| Immunity, Innate | 1 | 2017 | 375 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 512 | 0.380 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1717 | 0.380 |
Why?
|
| Humans | 36 | 2025 | 124705 | 0.380 |
Why?
|
| Metformin | 1 | 2013 | 152 | 0.370 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 1695 | 0.360 |
Why?
|
| Biomarkers | 3 | 2018 | 3083 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 257 | 0.320 |
Why?
|
| Neutrophils | 2 | 2021 | 382 | 0.310 |
Why?
|
| Middle Aged | 15 | 2021 | 26884 | 0.280 |
Why?
|
| Aged | 13 | 2021 | 19830 | 0.260 |
Why?
|
| Adult | 14 | 2021 | 29554 | 0.250 |
Why?
|
| Female | 19 | 2024 | 66577 | 0.250 |
Why?
|
| Male | 19 | 2024 | 61317 | 0.230 |
Why?
|
| Dysbiosis | 1 | 2025 | 122 | 0.220 |
Why?
|
| Immunoglobulin A | 1 | 2024 | 208 | 0.210 |
Why?
|
| Disease Management | 2 | 2025 | 522 | 0.210 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2022 | 8 | 0.210 |
Why?
|
| Age Factors | 3 | 2018 | 2807 | 0.200 |
Why?
|
| Genetic Testing | 2 | 2019 | 1002 | 0.200 |
Why?
|
| Adolescent | 8 | 2024 | 19221 | 0.200 |
Why?
|
| Splenomegaly | 1 | 2022 | 34 | 0.200 |
Why?
|
| Rubella virus | 1 | 2021 | 9 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.190 |
Why?
|
| Rubella | 1 | 2021 | 21 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6584 | 0.190 |
Why?
|
| Immunologic Factors | 3 | 2017 | 175 | 0.190 |
Why?
|
| Granuloma | 1 | 2021 | 68 | 0.180 |
Why?
|
| Eosinophilia | 1 | 2022 | 100 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2024 | 13882 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 40 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 249 | 0.180 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 50 | 0.180 |
Why?
|
| Child | 9 | 2024 | 24173 | 0.180 |
Why?
|
| Biodiversity | 1 | 2021 | 64 | 0.180 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 142 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2024 | 16263 | 0.170 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 434 | 0.170 |
Why?
|
| Risk Factors | 4 | 2022 | 10249 | 0.150 |
Why?
|
| Phylogeny | 1 | 2021 | 696 | 0.150 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2018 | 8 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 330 | 0.150 |
Why?
|
| Cough | 1 | 2019 | 88 | 0.150 |
Why?
|
| Serogroup | 1 | 2018 | 59 | 0.150 |
Why?
|
| Infant | 5 | 2024 | 12384 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2418 | 0.150 |
Why?
|
| Macrophages | 1 | 2021 | 621 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 546 | 0.140 |
Why?
|
| Chromatin | 1 | 2021 | 552 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 3715 | 0.140 |
Why?
|
| NADPH Oxidase 2 | 1 | 2017 | 40 | 0.140 |
Why?
|
| Sickness Impact Profile | 1 | 2017 | 36 | 0.140 |
Why?
|
| Bacteria | 1 | 2021 | 485 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2021 | 799 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 38 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 118 | 0.130 |
Why?
|
| Tumor Escape | 1 | 2017 | 62 | 0.130 |
Why?
|
| Health Status | 1 | 2018 | 374 | 0.130 |
Why?
|
| Allergens | 1 | 2018 | 252 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 116 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 817 | 0.130 |
Why?
|
| Self Report | 1 | 2018 | 517 | 0.120 |
Why?
|
| Incidence | 3 | 2017 | 3115 | 0.120 |
Why?
|
| Food Hypersensitivity | 1 | 2018 | 153 | 0.120 |
Why?
|
| Prognosis | 3 | 2020 | 4620 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 673 | 0.120 |
Why?
|
| Sex Factors | 1 | 2018 | 1287 | 0.120 |
Why?
|
| Inflammation | 1 | 2021 | 1440 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3415 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2093 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1492 | 0.100 |
Why?
|
| Whipple Disease | 1 | 2011 | 6 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 1530 | 0.090 |
Why?
|
| Registries | 1 | 2017 | 1429 | 0.090 |
Why?
|
| Prevalence | 1 | 2017 | 2446 | 0.090 |
Why?
|
| Pregnancy | 1 | 2022 | 7171 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 444 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 119 | 0.080 |
Why?
|
| United States | 3 | 2019 | 10866 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 265 | 0.070 |
Why?
|
| Immunoglobulin E | 2 | 2018 | 160 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 438 | 0.070 |
Why?
|
| Animals | 3 | 2018 | 34235 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4534 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 2057 | 0.060 |
Why?
|
| Cytokines | 2 | 2021 | 1286 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2021 | 12364 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1270 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2022 | 251 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2021 | 28 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 118 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 4799 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 8 | 0.050 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2021 | 15 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 74 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2024 | 434 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 185 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 298 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 439 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 476 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2021 | 214 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 684 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 737 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2021 | 414 | 0.040 |
Why?
|
| Skin Tests | 1 | 2018 | 75 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 533 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1694 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 190 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 443 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 697 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 534 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 31 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 59 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 568 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1006 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Stem Cells | 1 | 2021 | 706 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 242 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2756 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 591 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2161 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 752 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 313 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 95 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 172 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 554 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2055 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 778 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 596 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1896 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2043 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 1196 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1396 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 882 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 1176 | 0.020 |
Why?
|
| Asthma | 1 | 2019 | 753 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1757 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3444 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6323 | 0.020 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2011 | 74 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1686 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5154 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 191 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 151 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2885 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2900 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2011 | 492 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5845 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3154 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2011 | 852 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8163 | 0.010 |
Why?
|